The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a new era, the race is on to deliver more effective, patient-centered treatments.

This year, dive into novel mechanisms of action, non-invasive biomarkers, and strategic combination and sequential therapies. Hear from experts at Eli Lilly, Pfizer, Takeda, Madrigal, Akero, 89 Bio, and more as they share cutting-edge research and clinical strategies targeting diverse patient populations.

Join 60+ MASH scientists and drug developers, gain critical insights, and build meaningful collaborations over 10+ hours of dedicated networking. Don’t miss the Pre-Conference Combination & Sequential Therapy Day for a focused deep dive into emerging treatment approaches.

Find out more now: https://ter.li/d9r0pm